Company Insights

MGNX customer relationships

Explore interactive graphBrowse insights index
MGNX customer relationship map

MacroGenics (MGNX) — who pays, who partners and why it matters to investors

MacroGenics discovers and develops antibody-based oncology therapeutics and monetizes through a mix of product sales, strategic licensing and collaboration deals, milestone and royalty monetization, and fee-for-service manufacturing. The company’s revenue profile is driven by a small number of high-impact partnerships and transactional commercial arrangements—product sales historically centered on MARGENZA, non-dilutive milestone receipts from partners such as Incyte and Gilead, and monetization of royalty streams. For investors, the cash flow picture is therefore a hybrid of recurring spot sales, partner-driven milestone timing, and episodic monetization events.

Explore more company relationship intelligence at https://nullexposure.com/ for deeper due diligence.

What the relationship map tells investors

MacroGenics operates with a hybrid commercial posture: spot-sold product flows through specialty distributors and resellers, while advanced assets are commercialized via licensing and collaboration agreements that deliver large, lumpy payments. The company also acts as a service provider for contract manufacturing on a fee and reimbursement basis, creating a modest, predictable service revenue line alongside volatile milestone income. These characteristics create a revenue mix that is concentrated, timing-sensitive, and partially underwritten by blue‑chip partners.

Key takeaways:

  • High concentration: major partner milestones (Incyte, Gilead) materially affect annual revenue recognition.
  • Contracting posture: product sales are spot contracts with distributors; manufacturing engagements are scheduled service contracts reimbursed for materials and costs.
  • Maturity and criticality: collaborations with large pharmas are strategic and capital‑intensive; manufacturing relationships reduce capital expenditure but introduce counterparty execution risk.

For full coverage and customized reports, visit https://nullexposure.com/.

Relationship roll call — the filings and press that matter

Below I list every relationship item cited in company filings and news, with a concise plain‑English summary and source note for each result in the dataset.

Ajinomoto Bio-Pharma Services

MacroGenics relies on Ajinomoto for contract fill-finish services for current and future product candidates, indicating outsourced downstream manufacturing for finished drug product. Source: MacroGenics FY2024 Form 10‑K.

Gilead Sciences, Inc. (collaboration / option)

MacroGenics entered an exclusive option and collaboration agreement in October 2022 with Gilead to develop and commercialize MGD024 and to create additional bispecific research programs using the DART platform. Source: MacroGenics FY2024 Form 10‑K.

Incyte Corporation (license / manufacturing services)

MacroGenics licensed retifanlimab (MGA012) to Incyte under a global collaboration; MacroGenics retains rights to develop combination uses and also entered a separate agreement to provide manufacturing services for Incyte bulk drug substance over a multi‑year period. Source: MacroGenics FY2024 Form 10‑K.

TerSera Therapeutics LLC (announcement of acquisition of global rights)

MacroGenics announced in October 2024 that TerSera Therapeutics would acquire global rights to MARGENZA, shifting commercialization responsibility away from MacroGenics. Source: MacroGenics FY2024 Form 10‑K (October 2024 announcement).

TerSera Therapeutics, LLC (transaction detail / proceeds)

In November 2024 MacroGenics sold global rights to MARGENZA to TerSera for an upfront payment of $40.0 million, providing immediate non‑dilutive capital. Source: MacroGenics FY2024 Form 10‑K (November 2024 closing).

DRI Healthcare Trust (royalty monetization buyer)

MacroGenics sold its royalty interest in TZIELD (teplizumab) to a DRI Healthcare Trust subsidiary for up to $200 million, converting a future revenue stream into upfront proceeds. Source: CityBiz news report on the royalty sale (reporting on the FY2023 transaction).

Gilead (additional partnering proceeds reported)

MacroGenics reported an additional $75 million in partnering proceeds from Sanofi and Gilead in its Q3 2025 results, signaling continued cash inflows from collaboration milestones and asset sales. Source: MacroGenics press release reported on GlobeNewswire, Q3 2025.

Sanofi (Provention / partnering proceeds context)

Sanofi (through the Provention asset sale reference) contributed to non‑dilutive proceeds recognized by MacroGenics, with $50 million noted under the Provention (Sanofi) Asset Purchase Agreement in 2025. Source: MacroGenics Q3 2025 financial release on GlobeNewswire.

Incyte (milestone revenue impact)

MacroGenics reported that a $100 million milestone recognized under the Incyte License Agreement in 2024 drove a large portion of 2024 revenue, highlighting the magnitude of partner milestone payments to company topline. Source: Yahoo Finance / company Q4 2024 and FY2024 reporting (summary of milestone recognition).

Gilead (historic deal economics coverage)

Press coverage documented Gilead’s original opt‑in economics—reporting up to $1.7 billion in potential payments tied to the MGD024 collaboration—illustrating the strategic and financial scale of that partnership. Source: FierceBiotech coverage of the 2022 Gilead collaboration.

Emergent BioSolutions (manufacturing services customer)

MacroGenics entered agreements in August and December 2023 to provide manufacturing services producing certain Emergent bulk drug substances, under which MacroGenics receives payments and cost reimbursement tied to manufacturing schedules. Source: MacroGenics FY2024 Form 10‑K.

Incyte (strategic collaboration mention in later filings)

MacroGenics continues to leverage strategic collaborations with Incyte and Gilead to develop and commercialize product candidates and to provide non‑dilutive funding. Source: TradingView news summarizing MacroGenics’ SEC filings, FY2025 references.

Gilead (opt-in timing)

Investor communiques and media noted that Gilead’s opt‑in decision points could fall within the calendar year, which would drive milestone recognition and materially affect short‑term revenue. Source: Yahoo Finance coverage around FY2025 commentary.

TerSera Therapeutics (sale completed and use of proceeds)

Analysts and press noted the MARGENZA sale to TerSera provided MacroGenics with non‑dilutive capital to invest in its clinical pipeline and R&D. Source: Yahoo Finance FY2025 reporting.

Zai Lab (regional licensing)

Under a November 2018 license and collaboration, Zai Lab holds rights to develop margetuximab in mainland China, Hong Kong, Macau and Taiwan, representing a geographically carved commercialization arrangement. Source: MacroGenics FY2024 Form 10‑K.

Provention (Sanofi) (milestone comparison)

MacroGenics cited Provention/Sanofi milestone timing in comparing revenue recognition across years—$50 million recognized under that agreement in 2025 versus larger Incyte milestones in 2024. Source: MacroGenics Q3 2025 financial release on GlobeNewswire.

Operational constraints and investor implications

From the company disclosures, several company‑level signals shape the operating model:

  • Spot contract sales: Product revenue arises from written contracts with single delivery obligations; revenue is recognized on delivery, which concentrates timing risk around shipment events.
  • Distributor / reseller flow: Product sales are recorded as amounts due from specialty distributors who then resell to healthcare providers, adding a layer of counterparty credit and channel risk.
  • Service provider role: MacroGenics frequently functions as a manufacturing service provider, receiving scheduled payments and cost reimbursement—this reduces fixed capex but creates service delivery and margin variability.
  • Core product concentration: Historical product sales were driven by MARGENZA until its divestiture, indicating prior concentration in a single marketed product.

These signals mean investors must price MacroGenics for lumpy, partner‑driven cashflows, operational execution risk on outsourced manufacturing, and reliance on a small number of commercialization and licensing relationships.

Bottom line and next steps

MacroGenics’ commercial model blends transactional product sales, strategic licensing deals that produce large milestone payments, and fee‑for‑service manufacturing relationships. Investors should treat upcoming partner opt‑ins, milestone schedules, and any further royalty monetizations as primary drivers of near‑term valuation volatility.

For tailored relationship mapping and real‑time partner impact analysis, visit https://nullexposure.com/.

If you want a focused brief on a particular partner (Gilead, Incyte, TerSera) or a timeline of potential milestone triggers, request a custom report at https://nullexposure.com/ and we will prepare a concise investor memo.